Utility of the 4C ISARIC mortality score in hospitalized COVID-19 patients at a large tertiary Saudi Arabian center
Keywords:
ISARIC, mortality, predictor, COVID-19, Saudi Arabia, utilityAbstract
Background: The International Severe Acute Respiratory and Emerging Infections Consortium (ISARIC) 4C mortality score has been used before as a valuable tool for predicting mortality in COVID-19 patients. We aimed to address the utility of the 4C score in a well-defined Saudi population with COVID-19 admitted to a large tertiary referral hospital in Saudi Arabia.
Methods: A retrospective study was conducted that included all adult COVID‑19 patients admitted to the Armed Forces Hospital Southern Region (AFHSR), between January 2021 and September 2022. The receiver operating characteristic (ROC) curve depicted the diagnostic performance of the 4C Score for mortality prediction.
Results: A total of 1,853 patients were enrolled. The ROC curve of the 4C score had an area under the curve of 0.73 (95% CI: 0.702-0.758), p<0.001. The sensitivity and specificity with scores >8 were 80% and 58%, respectively, the positive and negative predictive values were 28% and 93%, respectively. Three hundred and sixteen (17.1%), 638 (34.4%), 814 (43.9%), and 85 (4.6%) patients had low, intermediate, high, and very high values, respectively. There were significant differences between survivors and non-survivors with regard to all variables used in the calculation of the 4C score. Multivariable logistic regression analysis revealed that all components of the 4C score, except gender and O2 saturation, were independent significant predictors of mortality.
Conclusions: Our data support previous international and Saudi studies that the 4C mortality score is a reliable tool with good sensitivity and specificity in the mortality prediction of COVID-19 patients. All components of the 4C score, except gender and O2 saturation, were independent significant predictors of mortality. Within the 4C score, odds ratios increased proportionately with an increase in the score value. Future multi-center prospective studies are warranted.
References
Barry M, Ghonem L, Alsharidi A, Alanazi, A, Alotaibi NH, et al. Coronavirus disease-2019 pandemic in the Kingdom of Saudi Arabia: mitigation measures and hospital preparedness. J Nat Sci Med 2020; 3:155-8.
Struyf T, Deeks JJ, Dinnes J, Takwoingi Y, Davenport C, Mg Leeflang M, et al. Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19 disease. Cochrane Database Syst Rev 2020;7:CD013665.
Wynants L, Calester BV, Collins GS, et al. Prediction models for diagnosis and prognosis of covid-19: systematic review and critical appraisal. BMJ 2020;369:m1328.
van Dam PM, Zelis N, van Kuijk SM, Linkens AE, Brüggemann RA, Spaetgens B, et al. Performance of prediction models for short‑term outcome in COVID‑19 patients in the emergency department: A retrospective study. Ann Med 2021;53:402‑9.
Covino M, De Matteis G, Burzo ML, Russo A, Forte E, Carnicelli A, et al. Predicting in‑hospital mortality in COVID‑19 older patients with specifically developed scores. J Am Geriatr Soc 2021;69:37‑43.
Knight SR, Ho A, Pius R, Buchan I, Carson G, Drake TM, et al. Risk stratification of patients admitted to hospital with COVID‑19 using the ISARIC WHO Clinical characterisation protocol: Development and validation of the 4C mortality score. BMJ 2020;370:m3339.
Song Y, Zheng S, Li L, Zhang X, Zhang X, Huang Z, et al. Deep learning enables accurate diagnosis of novel coronavirus (COVID‑19) with CT images. IEEE/ACM Trans Comput Biol Bioinform 2021;18:2775‑80.
Jones A, Pitre T, Junak M, et al. External validation of the 4C mortality score among COVID‑19 patients admitted to hospital in Ontario, Canada: a retrospective study. Sci Rep 2021;11:18638.
Kuroda S, Matsumoto S, Sano T, Kitai T, Yonetsu T, Kohsaka S, et al. External validation of the 4C Mortality Score for patients with COVID-19 and pre-existing cardiovascular diseases/risk factors. BMJ Open 2021;11:e052708.
Aletreby WT, Mumtaz SA, Shahzad SA, Ahmed I, Alodat MA, Gharba M, et al. External validation of 4C ISARIC mortality score in critically ill COVID‑19 patients from Saudi Arabia. Saudi J Med Med Sci 2022;10:19-24.
Mohamed RAE, Abdelsalam EM, Maghraby HM, Al Jedaani HS, Rakha EB, Hussain K, et al. Performance features and mortality prediction of the 4C Score early in COVID-19 infection: a retrospective study in Saudi Arabia. J Investig Med 2022;70:421-7.
Ministry of Health. Saudi MoH Protocol for patients suspected of/confirmed with COVID‑19. Available from: https://www.moh.gov.sa/en/Ministry/MediaCenter/Publications/Documents/MOH-therapeutic-protocol-for-COVID-19.pdf
Verma AA, Hora T, Jung HY, Fralick M, Malecki SL, Lapointe-Shaw L, et al. Characteristics and outcomes of hospital admissions for COVID-19 and influenza in the Toronto area. CMAJ 2021;193:E410-E418.
Centers for Disease Control and Prevention. David J. Sencer CDC Museum: In Association with the Smithsonian Institution: CDC Museum COVID-19 Timeline. Available from: https://www.cdc.gov/museum/pdf/ghomuseumpresssheet.pdf
AlBahrani S, AlAhmadi N, Hamdan S, Elsheikh N, Osman A, Almuthen S, et al. Clinical presentation and outcome of hospitalized patients with COVID-19 in the first and second waves in Saudi Arabia. Int J Infect Dis 2022;118:104-8.
Wellbelove Z, Walsh C, Perinpanathan T, Lillie P, Barlow G. Comparing the 4C mortality score for COVID‑19 to established scores (CURB65, CRB65, qSOFA, NEWS) for respiratory infection patients. J Infect 2021;82:414‑51.
Liang W, Liang H, Ou L, Chen B, Chen A, Li C, et al. Development and validation of a clinical risk score to predict the occurrence of critical illness in hospitalized patients with COVID-19. JAMA Intern Med 2020;180:1081-9.
Haimovich AD, Ravindra NG, Stoytchev S, Young HP, Wilson FP, van Dijk D, et al. Development and validation of the quick COVID-19 severity index: a prognostic tool for early clinical decompensation. Ann Emerg Med 2020;76:442-53.
Morgan RJM, Williams F, Wright MM. Early warning scoring system for detecting developing critical illness. Clin Intensive Care 1997;8:100.
Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO clinical characterisation protocol: prospective observational cohort study. BMJ 2020;369:m1985.
Dhont S, Derom E, Van Braecke E, Depuydt P, Lambrecht BN. The pathophysiology of ‘happy’ hypoxemia in COVID-19. Respir Res 2020;21:198.
Gupta RK, Marks M, Samuels THA, Luintel A, Rampling T, Chowdhury H, et al. Systematic evaluation and external validation of 22 prognostic models among hospitalised adults with COVID-19: an observational cohort study. Eur Respir J 2020;56:2003498.
Sellers J, Change J, Jones J, Hintze TD. Patients with moderate to severe COVID-19 outcomes on remdesivir according to baseline 4C mortality score. Pulm Pharmacol Ther 2023;78:102188.
Alwazzeh MJ, Subbarayalu AV, Abu Ali BM, Alabdulqader R, Alhajri M, Alwarthan SM, et al. Performance of CURB-65 and ISARIC 4C mortality scores for hospitalized patients with confirmed COVID-19 infection in Saudi Arabia. Inform Med Unlocked 2023;39:101269.
de Jong VMT, Rousset RZ, Antonio-Villa NE, Buenen AG, Van Calster B, Bello-Chavolla OY, et al. Clinical prediction models for mortality in patients with covid-19: external validation and individual participant data meta-analysis. BMJ 2022;378:e069881.
Albai O, Frandes M, Sima A, Timar B, Vlad A, Timar R. Practical applicability of the ISARIC-4C score on severity and mortality due to SARS-CoV-2 infection in patients with type 2 diabetes. Medicina (Kaunas) 2022;58:848.
Knight SR, Gupta RK, Ho A, Pius R, Buchan I, Carson G, et al. ISARIC4C investigators. Prospective validation of the 4C prognostic models for adults hospitalised with COVID-19 using the ISARIC WHO clinical characterisation protocol. Thorax 2022;77:606-15.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Mattioli 1885 has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
How to Cite
